These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9329583)

  • 1. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
    Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G
    Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia.
    Nakamura T; Scorilas A; Stephan C; Jung K; Soosaipillai AR; Diamandis EP
    Cancer Res; 2003 Oct; 63(19):6543-6. PubMed ID: 14559849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The percentage of free prostate specific antigen used in detecting prostate cancer].
    Yang L; Fang Z; Song J; Deng S
    Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA; Kuriyama M
    Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
    de la Taille A; Houlgatte A; Houdelette P; Berlizot P; Ramirez J; Ricordel I
    Prog Urol; 1997 Apr; 7(2):240-5. PubMed ID: 9264766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
    Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
    Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Determination of free PSA in 85 consecutive cases with increased total PSA].
    Rothen JP; Vuillemin R
    Schweiz Med Wochenschr; 1996 Dec; 126(49):2141-3. PubMed ID: 8999503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free-to-total prostate-specific antigen serum concentrations in patients with prostate cancer and benign prostatic hyperplasia.
    Wolff JM; Borchers H; Effert PJ; Habib FK; Jakse G
    Br J Urol; 1996 Sep; 78(3):409-13. PubMed ID: 8881952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ratio of free to total prostate specific antigen: an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate?
    Reiter W; Stieber P; Schmeller N; Nagel D; Jansen HM; Schambeck C; Fabricius PG; Pahl H; Mattes M; Constabel H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2987-91. PubMed ID: 9329582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First clinical results with Enzymun-Test for free PSA.
    Gilson G; Lamy S; Humbel RL
    Anticancer Res; 1997; 17(4B):2861-4. PubMed ID: 9329548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
    Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
    Jung K; Meyer A; Lein M; Rudolph B; Schnorr D; Loening SA
    J Urol; 1998 May; 159(5):1595-8. PubMed ID: 9554361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.